Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Uwagawa T, Sakamoto T, Gocho T, Shiba H, et al. PLoS One 2022;17:e0267623.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Uwagawa T, Sakamoto T, Gocho T, Shiba H, et al. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. PLoS One 2022;17:e0267623.
PMID: 35544539